Beam Therapeutics Inc. Common Stock Earnings Dividend

Beam Therapeutics Inc. Common Stock’s revenue jumped 324.87% since last year same period to $31.74Mn in the Q1 2026. On a quarterly growth basis, Beam Therapeutics Inc. Common Stock has generated -72.19% fall in its revenue since last 3-months.

Beam Therapeutics Inc. Common Stock’s net profit jumped 13.68% since last year same period to $-94.32Mn in the Q1 2026. On a quarterly growth basis, Beam Therapeutics Inc. Common Stock has generated -138.61% fall in its net profits since last 3-months.

Beam Therapeutics Inc. Common Stock’s net profit margin jumped 79.68% since last year same period to -297.18% in the Q1 2026. On a quarterly growth basis, Beam Therapeutics Inc. Common Stock has generated -238.81% fall in its net profit margins since last 3-months.

Beam Therapeutics Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -1.13 - a -11.88% fall from last quarter’s estimates.

Beam Therapeutics Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -1.13.

Beam Therapeutics Inc. Common Stock’s earning per share (EPS) jumped 26.61% since last year same period to -0.91 in the Q1 2026. This indicates that the Beam Therapeutics Inc. Common Stock has generated 26.61% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Beam Therapeutics Inc. Common Stock’s return on assets (ROA) stands at -0.16.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Beam Therapeutics Inc. Common Stock’s return on equity (ROE) stands at -0.06.